Why a pioneering plan to distribute COVID vaccines equitably must succeed
COVAX is key to both immunizing the world’s poorest people and ending the pandemic.
Science advisers: publish evidence behind COVID vaccine dosing strategy
Countries that change established coronavirus vaccine schedules must be transparent, both to maintain public trust and so others can benefit from their knowledge.
Beyond Politics — Promoting Covid-19 Vaccination in the United States
The United States has invested more than $10 billion in Operation Warp Speed to fast-track SARS-CoV-2 vaccines from conception to market in 1 year. The result is 11 candidates reaching the final stage of Food and Drug Administration testing — a phenomenal improvement over past development timelines. Indeed, two SARS-CoV-2 vaccines are already available to Americans.
What To Expect Of The COVID-19 Pandemic In 2021: Ask Our Experts
Join our medical expert and wellness editor for a conversation about vaccines, when schools and businesses may reopen, and if life will return to normal.
Covid-19 Live Updates: Scientists Debate Holding Back Second Vaccine Dose
There is international disagreement on which approach will better contain the virus. Public officials have weighed whether to receive early shots to demonstrate their safety.
As Rollout Falters, Scientists Debate New Vaccination Tactics
Should second doses be delayed? Should most adults receive half-doses? Scientists are pondering ways to get more shots into more arms.
Maintaining Safety with SARS-CoV-2 Vaccines
To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials
An Essential Worker’s List of Pandemic Chores for the Kids
Sorry I had to leave before you woke up. You’re right, it isn’t fair.
Please empty the dishwasher today. And brush your teeth.
Remember to feed the dog. He will die if no one remembers to do this.
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor.
Older Adults’ Perspectives on a COVID-19 Vaccine
As of December 4, 2020, cases of novel coronavirus disease 2019 (COVID-19) have topped 14.3 million in the US with nearly 300 000 associated deaths. While mitigation measures such as social distancing, use of face coverings, and avoidance of crowds can help keep case counts in check, a safe and effective COVID-19 vaccine will be essential to ending the pandemic.
Leading COVID-19 vaccine candidates rely on new genetic technologies that have fast-tracked development and testing. This video explains the principles underlying the leading DNA, messenger RNA (mRNA), and viral vector vaccine candidates, and how they might induce immunity to SARS-CoV-2 infection.